The DOI matches its Crossref record; the references it cites are not checked yet.
Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase
Open accessAbstract
BACKGROUND: A decrease in fatty acid amide hydrolase (FAAH) activity increases the levels of endogenous analogues of cannabinoids, or endocannabinoids. FAAH inhibitors have shown analgesic and antiinflammatory activity in animal models, and some have been tested in phase 1 and 2 studies. In a phase 1 study, BIA 10-2474, an orally administered reversible FAAH inhibitor, was given to healthy volunteers to assess safety. METHODS: Single doses (0.25 to 100 mg) and repeated oral doses (2.5 to 20 mg for 10 days) of BIA 10-2474 had been administered to 84 healthy volunteers in sequential cohorts; no severe adverse events had been reported. Another cohort of participants was then assigned to placebo (2 participants) or 50 mg of BIA 10-2474 per day (6 participants). This report focuses on neurologic adverse events in participants in this final cohort. A total of 4 of the 6 participants who received active treatment consented to have their clinical and radiologic data included in this report. RESULTS: An acute and rapidly progressive neurologic syndrome developed in three of the four participants starting on the fifth day of drug administration. The main clinical features were headache, a cerebellar syndrome, memory impairment, and altered consciousness. Magnetic resonance imaging showed bilateral and symmetric cerebral lesions, including microhemorrhages and hyperintensities on fluid-attenuated inversion recovery and diffusion-weighted imaging sequences predominantly involving the pons and hippocampi. One patient became brain dead; the condition of two patients subsequently improved, but one patient had residual memory impairment, and the other patient had a residual cerebellar syndrome. One patient remained asymptomatic. CONCLUSIONS: An unanticipated severe neurologic disorder occurred after ingestion of BIA 10-2474 at the highest dose level used in a phase 1 trial. The underlying mechanism of this toxic cerebral syndrome remains unknown.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It was therefore quite unexpected that severe neurological symptoms occurred in the third cohort on the fifth day of administration, which caused the death of one of the volunteers and neurological toxicity in four others.”
In the citing paper
“This revision followed a tragic event that happened in January 2016 during an FIH programme with BIA 10-2474, a fatty acid amide hydrolase (FAAH) inhibitor that enhances endogenous endocannabinoid concentrations being developed by BIAL [7].”
In the citing paper
“In contrast, BIA 10-2474 (Section 7.3) and torcetrapib (Section 7.5) are off-target toxicities that surfaced only at clinical exposures.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [73]
In the citing paper
“In 2016, the fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474 caused fatal neurological injury in one volunteer and severe brain damage in others during a multiple-ascending-dose study.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [73]
In the citing paper
“Preclinical species showed adequate tolerability, but off-target effects on lipases beyond FAAH led to CNS toxicity unique to humans at the administered doses [73,74].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [73]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 5 · Cited by 171
Metadata
- Authors
- Kerbrat, A., Ferré, J.-C., Fillatre, P., Ronzière, T., Vannier, S., Carsin-Nicol, B., Lavoué, S., Vérin, M., Gauvrit, J.-Y., Le Tulzo, Y., & Edan, G.
- Affiliations
- Institut national de recherche en sciences et technologies du numérique (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-03
- Volume
- 375
- Issue
- 18
- Pages
- 1717-1725
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2548310016
- Cited by
- 171
- References
- 5
- Citations by year
- 2026: 10 · 2025: 5 · 2024: 9 · 2023: 8 · 2022: 11 · 2021: 19 · 2020: 31 · 2019: 22 · 2018: 23 · 2017: 26 · 2016: 7
- FWCI
- 21.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Clinical Neurology › Neurological Complications and Syndromes
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- fatty acid amide hydrolase inhibitors, endocannabinoids, neurological adverse events, drug toxicity, cerebellar syndrome, memory impairment, brain lesions, passive optical networks, hippocampus, drug safety
- MeSH terms
- Fatty Acid Amide Hydrolases, Acute Disease, Administration, Oral, Adult, Amidohydrolases, Brain Death, Cerebellar Diseases, Cerebellum, Cerebral Hemorrhage, Consciousness Disorders, Cyclic N-Oxides, Double-Blind Method, Headache, Hippocampus, Humans, Magnetic Resonance Imaging, Male, Memory Disorders, Middle Aged, Pons, Pyridines, Gait Ataxia, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase. https://app.cochat.ai/papers/10.1056/nejmoa1604221
- The paper
- Kerbrat, A., Ferré, J.-C., Fillatre, P., Ronzière, T., Vannier, S., Carsin-Nicol, B., Lavoué, S., Vérin, M., Gauvrit, J.-Y., Le Tulzo, Y., & Edan, G. (2016). Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1604221
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.